相关实验视频
Updated: Feb 21, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.3K
在RET融合阳性乳头甲状腺癌的分子病变和治疗进步
Yuqing Wei1, Yan Zhang2, Zongjing Zhang3
1Department of Pathology, The Postgraduate Training Base of Jinzhou Medical University (The 960th Hospital of the PLA Joint Logistic Support Force), Jinan 250031, China; Department of Pathology, The 960th Hospital of the PLA Joint Logistic Support Force, Jinan 250031, China.
Pathology, research and practice
|February 19, 2026
概括
RET融合驱动乳头甲状腺癌 (PTC) 的生长. 选择性RET抑制剂显示出有希望的结果,但耐药性需要进一步研究以获得有效的精确治疗.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 乳头甲状腺癌 (PTC) 是最常见的内分泌恶性瘤.
- RET融合是PTC中关键的遗传驱动因素,与侵入性和不良预后有关.
研究的目的:
- 系统地审查RET聚变阳性PTC的分子病原性.
- 分析RET抑制剂的临床疗效和耐药性机制.
主要方法:
- 分子病原和临床研究的文献综述.
- 分析RET原瘤基因,融合事件,信号通路和抵抗机制.
主要成果:
- RET融合,特别是CCDC6-RET和NCOA4-RET,导致持续的通路激活.
- 选择性RET抑制剂 (selpercatinib,pralsetinib) 显示出有效性,包括在儿科和耐火病例中.
- 目标突变和绕道激活是关键的抵抗机制.
结论:
- 了解RET融合病原体对于精确的诊断和治疗至关重要.
- RET抑制剂提供了新的治疗途径,目前正在进行的研究解决了耐药性,以改善患者的治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
25
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
25
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
02:07Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K